Skip to main content

Table 1 Characteristics of included studies

From: The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials

  Study Country Study design Random method Blinding Duration Conventional diuretic Treatment Number of patients Age (mean ± SD) Sex (M/F) Serum Sodium Concentration (mmol/L)
1 Dominique Guyader (2002) Multicenter trail RCT NA Double-blind 1 d N palcebo 5 55.6 ± 10.1 3/2 139.0 ± 3.2
VPA-985 25 mg 4 58.5 ± 9.5 3/1 140.5 ± 2.1
VPA-985 50 mg 5 59.4 ± 6.0 5/0 135.7 ± 5.2
VPA-985 100 mg 4 61.2 ± 8.0 3/1 131.0 ± 6.0
VPA-985 200 mg 4 62.8 ± 5.8 3/1 139.0 ± 3.0
VPA-985 300 mg 5 49.0 ± 2.9 4/1 136.0 ± 2.1
2 Alexanderl. Gerbes (2003) Multicenter trail RCT Computerized randomization Double-blind 7 d NA palcebo 20 58 ± 2 15/5 127.3 ± 3.0
VPA-985 100 mg/d 22 54 ± 3 17/5 128.3 ± 4.1
VPA-985 200 mg/d 18 56 ± 3 14/4 126.4 ± 4.4
3 Florence Wong (2003) Multicenter trail RCT Computerized randomization NA 7 d Y palcebo 8 NA NA 127 ± 1
VPA-985 50 mg/d 8 126 ± 1
VPA-985 250 mg/d 10 122 ± 2
VPA-985 500 mg/d 7 125 ± 1
4 PJ THULUVAT H (2006) USA RCT NA Double-blind 1 d Y palcebo 6 50.5 ± 7.6 4/2 136 ± 2
RWJ-351647 1 mg 6 56.5 ± 5.2 4/2 136 ± 5
RWJ-351647 2 mg 6 51.5 ± 7 5/1 137 ± 2
RWJ-351647 5 mg 6 48.3 ± 1.2 5/1 136 ± 3
5 Pere Gines (2008) Multicenter trail RCT Computerized randomization Double-blind 14 d Y palcebo 28 55 ± 10 22/6 NA
Satavaptan 5 mg/d 28 57 ± 8 16/12
Satavaptan 12.5 mg/d 26 56 ± 9 19/7
Satavaptan 25 mg/d 28 59 ± 10 20/8
6 Florence Wong (2010) Multicenter trail RCT Computerized randomization Double-blind 12 weeks Y palcebo 36 60 ± 9 26/10 136 ± 4
Satavaptan 5 mg/d 39 59 ± 9 32/7 133 ± 6
Satavaptan 12.5 mg/d 36 59 ± 9 28/8 135 ± 5
Satavaptan 25 mg/d 40 60 ± 11 29/11 134 ± 5
7 Pere Gines (2010) Multicenter trail RCT Computerized randomization Double-blind 14 d Y palcebo 35 58 ± 9 22⁄13 137 ± 3
Satavaptan 5 mg/d 40 58 ± 9 30⁄10 137 ± 3
Satavaptan 12.5 mg/d 35 57 ± 8 26⁄9 136 ± 4
Satavaptan 25 mg/d 38 55 ± 9 25⁄13 136 ± 2
8 Andres Cardenas (2012) USA RCT Stratified random Double-blind 30 d Y Placebo 57 55 ± 9 38/19 NA
Tolvaptan 15-60 mg/d 63 52 ± 8 50/13
9a Florence Wong (2012)a Multicenter trail RCT Stratified random Double-blind 52 weeks Y placebo 230 56.4 ± 9.2 168/62 NA
Satavaptan 5 or 10 mg/d 232 56.6 ± 10.2 158/74
9b Florence Wong (2012)b Multicenter trail RCT Stratified random Double-blind 52 weeks Y placebo 168 57.0 ± 9.8 113/55 NA
Satavaptan 5 or 10 mg/d 328 58.9 ± 10.0 237/91
9c Florence Wong (2012)c Multicenter trail RCT Stratified random Double-blind 52 weeks N placebo 80 56.2 ± 9.9 50/30 NA
Satavaptan 5 or 10 mg/d 160 56.4 ± 9.6 108/52
10 Isao Sakaida (2014) Japan RCT NA Double-blind 7 d Y placebo 80 NA 49/31 135.7 ± 4.1
tolvaptan 7.5 mg/d 82 52/30 135.3 ± 4.5
11 Kiwamu Okita (2014) Japan RCT NA Double-blind 7 d Y placebo 26 64 ± 10 17/9 NA
tolvaptan 7.5 mg/d 25 65 ± 9 18/7
tolvaptan 15 mg/d 25 65 ± 10 21/4
tolvaptan 30 mg/d 25 63 ± 10 15/10
12 Pere Gines (2007) Multicenter trail RCT NA Single-blind 52 weeks Y placebo 47 NA NA 132.5
satavaptan 5 mg/d-50 mg/d 26 131.7
13 Pere Gines (2008)’ Multicenter trail RCT NA Single-blind 52 weeks Y placebo 92 NA NA NA
satavaptan 5 mg/d-50 mg/d 47
14 Florence Wong (2009) Multicenter trail RCT NA Single-blind 52 weeks Y placebo 48 NA NA NA
satavaptan 5 mg/d-50 mg/d 186